Triple
T5160993
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Hodgkin lymphoma |
E116434
|
entity |
| Predicate | treatedWith |
P2367
|
FINISHED |
| Object |
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
|
E499491
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: BEACOPP regimen | Statement: [Hodgkin lymphoma, treatedWith, BEACOPP regimen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: BEACOPP regimen Context triple: [Hodgkin lymphoma, treatedWith, BEACOPP regimen]
-
A.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
D.
REGN-EB3
REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: BEACOPP regimen Triple: [Hodgkin lymphoma, treatedWith, BEACOPP regimen]
Generated description
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: BEACOPP regimen Target entity description: The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
A.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
D.
REGN-EB3
REGN-EB3 is a monoclonal antibody cocktail developed by Regeneron to treat Ebola virus disease, shown to significantly reduce mortality in clinical trials.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69bd445edb3881909b93b34d260717fc |
completed | March 20, 2026, 12:58 p.m. |
| NER | Named-entity recognition | batch_69bd79073a54819080cd1e8de6fe906a |
completed | March 20, 2026, 4:42 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69bed92b3ab48190900cf5c246dba433 |
completed | March 21, 2026, 5:45 p.m. |
| NEDg | Description generation | batch_69beda3bfee08190a6e1d8b06739cade |
completed | March 21, 2026, 5:49 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69beda93175481908c79010c7fe6897e |
completed | March 21, 2026, 5:51 p.m. |
Created at: March 20, 2026, 1:44 p.m.